1,208
Participants
Start Date
January 14, 2019
Primary Completion Date
March 4, 2024
Study Completion Date
March 4, 2024
Multivalent Group B streptococcus vaccine
Various formulations at three dose levels
Placebo
Saline control
Respiratory and Meningeal Pathogens Research Unit (RMPRU), Soweto
Wits Reproductive Health and HIV Institute, Johannesburg
Empilweni Services and Research Unit (ESRU), Coronationville
Charlotte Maxeke Johannesburg Academic Hospital, Parktown
FAMCRU, Parow Valley
Khayelitsha District Hospital (KDH), Khayelitsha
Michael Mapongwana Community Health Centre, Khayelitsha
Site B, Khayelitsha
Emerson Clinical Research Institute, Washington D.C.
Sentara Leigh Hospital, Norfolk
The Group for Women, Norfolk
Tidewater Physicians for Women, Norfolk
Lowcountry Women's Specialists, Summerville
Summerville Medical Center, Summerville
Coastal Pediatric Research, Summerville
Velocity Clinical Research, Mobile
Boeson Research, Missoula
Community Hospital, Missoula
The Birth Center, Missoula
Frontier Pediatric Care (Follow-Up Visits for Infant Participants), Lincoln
Bryan Women's Care Physicians (Maternal Visits & Obstetric Exams), Lincoln
Be Well Clinical Studies, Lincoln
Meridian Clinical Research, Hastings
North Oaks Medical Center, Hammond
North Oaks Obstetrics & Gynecology, Hammond
Lakeview Regional Medical Center, Covington
MedPharmics, Covington
St. Tammany Parish Hospital, Covington
Velocity Clinical Research, Slidell
Clinical Research Prime, Idaho Falls
Clinical Research Prime Rexburg, Rexburg
Velocity Clinical Research, Phoenix, Phoenix
Chemidox Clinical Trials Inc., Lancaster
Chemidox Clinical Trials Inc, Lancaster
St George's University Hospitals NHS Foundation Trust, London
Lead Sponsor
Pfizer
INDUSTRY